MAZE logo

MAZE Maze Therapeutics Inc.

$26.43
$0.00
(0.00%)
Today
Closed $26.43
$0.00
(0.00%)
After Hours
37

Bearish Sentiment

How do you feel about MAZE?

Loading...
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
Stocktwits
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
Key PointsChief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026...
Nasdaq News: Markets
Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?
Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...
Nasdaq News: Markets
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...
Nasdaq News: Markets
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...
Yahoo! Finance: News
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts
Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...
MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $190,275.00 in Stock
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the sale, the insider directly...
MarketBeat